Monday at the International AIDS Society conference in Rome, an expanded session featured information on the HPTN 052 study, the Partners PrEP Study, and the Centers for Disease Control’s TDF2 study presented in a joint session titled Treatment Is Prevention: The Proof Is Here, on Monday. The results of these trials will fundamentally change the way we think about HIV prevention and treatment, although implementation of these approaches will likely prove as challenging as ever.
HPTN 052, sponsored by the HIV Prevention Trials Network, was the first randomized clinical trial to definitively indicate that an HIV-infected individual can reduce sexual transmission of HIV to an uninfected partner by beginning antiretroviral therapy sooner. The study involved 1,763 HIV-serodiscordant couples at 13 sites across Africa, Asia, and the Americas. The trial results were initially released in May 2011 on the recommendation of an independent data and safety monitoring board (DSMB) and Monday’s session was the first full presentation of the trial data.